For people whose neurological condition disrupts bowel control, a more predictable bathroom routine could be a meaningful improvement in daily life. DTI-117 is an investigational peptide being developed around that goal. New animal findings reported on October 13 support further study of a rapid, short-lived effect, with a first human study expected to follow.
News date: 2026-10-13 | Reviewed: October 15, 2026
What Is DTI-117 Used for in Research?
DTI-117 is a short-acting peptide that activates the neurokinin-2, or NK2, receptor. Dignify is developing it for on-demand bowel emptying, particularly in neurogenic bowel dysfunction. That condition involves disrupted nervous-system control of bowel function.
The intended benefit is practical: a response that can be planned around a care routine. This is a development goal, rather than an established treatment effect in patients. The NIDDK constipation overview explains that constipation can have multiple causes, including spinal cord or brain injuries.
How the New Study Worked
The company’s conference report describes experiments in eight conscious minipigs, with equal numbers of males and females. Investigators compared intramuscular DTI-117 with vehicle, the carrier without the active peptide. They examined responses across doses and included a crossover phase.
The report also measured drug exposure over time. Together, these experiments asked whether the peptide produced the intended response and whether its presence in the blood matched the proposed short duration. They were animal experiments, not a patient efficacy trial.
Results and Key Findings
Dignify reported increased bowel-emptying responses with increasing doses and responses occurring within minutes. The crossover findings supported activity compared with vehicle. Rapid absorption and a terminal half-life of roughly three to four minutes were consistent with a short-acting profile.
Higher doses also produced urinary responses and transient unwanted effects, including diarrhea, vomiting, lethargy and flushing. These findings are company-reported conference data. They support further investigation, while leaving the magnitude and acceptability of any benefit in people unresolved.
The Research in Plain English
Some treatment programs aim to keep a medicine active for days. This program asks whether a brief effect could be more useful. Imagine an intervention designed to help at a chosen moment rather than remain active throughout the day. That is the practical idea behind on-demand development.
The challenge is making that moment dependable. A quick response in a small animal study does not establish that a person can reliably plan a routine around it. Researchers still need to learn how variable the response is and whether unwanted effects can be separated from the intended effect.
Key Insights and Potential Benefits
A successful therapy could eventually make bowel care easier to schedule. The important outcome would be usable control, not merely evidence that a compound causes an animal to defecate. Those two questions are related, but they require different kinds of studies.
This is why the story may interest readers beyond peptide enthusiasts. A development program can target an ordinary activity with a large effect on independence. The potential benefit is understandable without specialist knowledge: a more manageable routine for someone whose neurological condition has made that routine difficult.
Why a Short Half-Life Matters—and What It Cannot Tell Us
Half-life describes how quickly the measured drug concentration falls by half during a defined phase of its disappearance. A short half-life helps explain why researchers are investigating brief exposure. It does not, by itself, establish exactly when every effect will stop.
Future reports should connect exposure with both the desired response and unwanted responses. That relationship would help determine whether there is a useful therapeutic window: enough activity to achieve the goal, with an acceptable treatment experience. The animal data cannot yet define that window for people.
Tolerability and the First Human Step
The company says a randomized, blinded, placebo-controlled Phase 1 study in healthy volunteers is expected to begin dosing in November 2026. It reports that the investigational application has received FDA clearance. Permission to begin research is distinct from approval to market a medicine.
A first study can clarify human exposure and tolerability, but healthy volunteers do not represent everyone living with neurological bowel dysfunction. Later research would need to include the intended patient population and examine repeatability, practical use and effects that matter to their daily care.
Synergistic Research Pairing and Related Compounds
The meaningful complementary work here pairs receptor biology with measurement of drug exposure and bowel function. No peptide combination was established by this report. It would be premature to describe DTI-117 as a stack partner for a gut-focused research compound.
For a different gut research topic, read our KPV explanation and the KPV laboratory catalogue entry. Those links concern a separate compound and research rationale. They do not establish substitution, synergy or a protocol for neurological bowel dysfunction.
What Readers Can Look Forward To
The next milestone is confirmation that human dosing has begun, followed by a clear account of tolerability and pharmacokinetics. Subsequent patient studies would need to measure whether the proposed on-demand effect delivers a predictable and useful result in practice.
A particularly informative future report would explain how often treatment achieves a satisfactory response and how patients evaluate the experience. That would bring the evidence closer to the real development goal: turning an encouraging biological response into greater control over an important part of everyday life.
Explore Our Research Tools
Explore the Peptide Calculator, Protocol Builder and Protocol Tracker for concentration calculations and organized research notes. These tools do not select a treatment or reproduce a study formulation. Browse the Compound Library for related compound background.
